Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.41 |
| ▸ | ARHGDIA | P52565 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417212 | 0.79 | RXRA (0.47) | ROCK2ROCK1ARHGDIAALDH1A1POLB | |
| SCHEMBL5404336 | 0.73 | ROCK2 (0.70) | ROCK2ROCK1ARHGDIA | |
| Hydrochloric Acid SCHEMBL5404775 | 0.72 | ROCK2 (0.69) | ROCK2ROCK1ARHGDIA | |
| SCHEMBL1980303 | 0.67 | ROCK2 (0.55) | ROCK2ROCK1ARHGDIAKMT2A | |
| SCHEMBL19538938 | 0.66 | HDAC8 (0.43) | ALDH1A1SMN1; SMN2LMNAKMT2ABRD4 | |
| SCHEMBL5425214 | 0.65 | ROCK2 (0.45) | ROCK2ROCK1ARHGDIAALDH1A1POLB | |
| SCHEMBL13106895 | 0.64 | CDC7 (0.45) | ALDH1A1HPGDBRD4CREBBP | |
| SCHEMBL5412656 | 0.64 | ROCK2 (0.73) | ROCK2ROCK1ARHGDIA | |
| SCHEMBL13106873 | 0.64 | FAAH (0.56) | ROCK2ROCK1ALDH1A1HPGDKMT2A | |
| SCHEMBL19538837 | 0.64 | SLC22A12 (0.46) | ALDH1A1POLBHPGDSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885ARHGDIA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.